DAPT recommendation
Contents
- 1 Current recommendation for DAPT duration after a percutaneous coronary intervention (PCI) for stable coronary syndromes is
- 2 Recommended duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) is at least
- 3 Most commonly prescribed antiplatelet therapy as monotherapy or combination therapy
- 4 DAPT recommendation
Current recommendation for DAPT duration after a percutaneous coronary intervention (PCI) for stable coronary syndromes is
[A] 6 months
[B] 12 months
[C] 18 months
[D] Lifelong
Recommended duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) is at least
[A] 6 months[B] 12 months
[C] 18 months
[D] Lifelong
Most commonly prescribed antiplatelet therapy as monotherapy or combination therapy
[A] Aspirin[B] Clopidogrel
[C] Ticagrelor
[D] Prasugrel
DAPT recommendation
Current recommendation for DAPT duration is
| Current recommendation for DAPT duration | |
| Stable ischemic heart disease | 6 months |
| Acute coronary syndrome | 12 months |
- Stable ischemic heart disease – 6 months
- Acute coronary syndrome (ACS) – 12 months
Current medical guidelines recommend a 6-month duration of DAPT for stable coronary disease and 12 months for acute coronary syndrome (ACS).
High bleeding risk
For patients at high bleeding risk, 1–3 months of DAPT may be better than 12 months to reduce the risk of major bleeding.
High ischemic risk
For patients at high ischemic risk, longer-duration DAPT may be reasonable.
Non-ACS
For patients with non-ACS, 1–3 months of DAPT is recommended for patients at high bleeding risk.
After PCI in patients presenting with chronic coronary syndrome, DAPT duration of 6 months is recommended. However, shortening to at least 1 month or extension up to ≥12 months is also supported by the guidelines in dependence of ischemic and bleeding risk.
